These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
938 related articles for article (PubMed ID: 24222194)
1. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab emtansine for HER2-positive advanced breast cancer. Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K; N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162 [TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536 [TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722 [TBL] [Abstract][Full Text] [Related]
5. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056 [TBL] [Abstract][Full Text] [Related]
6. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838 [TBL] [Abstract][Full Text] [Related]
7. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143 [TBL] [Abstract][Full Text] [Related]
8. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694 [TBL] [Abstract][Full Text] [Related]
9. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Squires H; Stevenson M; Simpson E; Harvey R; Stevens J Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972 [TBL] [Abstract][Full Text] [Related]
12. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807 [TBL] [Abstract][Full Text] [Related]
13. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Piwko C; Prady C; Yunger S; Pollex E; Moser A Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine in breast cancer. Dirix LY; Rutten A; Huget P; Dirix M Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114 [TBL] [Abstract][Full Text] [Related]
17. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Zhou X; Cella D; Cameron D; Amonkar MM; Segreti A; Stein S; Walker M; Geyer CE Breast Cancer Res Treat; 2009 Oct; 117(3):577-89. PubMed ID: 19153829 [TBL] [Abstract][Full Text] [Related]
18. Lapatinib for the treatment of HER2-overexpressing breast cancer. Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022 [TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]